Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of subcutaneous efgartigimod PH20 in adults with chronic inflammatory demyelinating polyneuropathy
MOH_2020-03-12_008767Phase 2Not yet recruiting
- Sponsor
- argenx
- Start
- Feb 2020
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of efgartigimod alfa in chronic inflammatory demyelinating polyneuropathy (CIDP) (4 arms), sponsored by argenx. Planned start Feb 2020; status: not yet recruiting.
02
Drugs
efgartigimod alfa
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on MOH_2020-03-12_008767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-03-12_008767.